The departure of the CEO overseeing Ozempic at Novo Nordisk reportedly began with a surprise announcement during a Microsoft Teams call. This move has sparked discussions within the pharmaceutical sector regarding leadership transitions and their impact on product lines such as Ozempic, which has been pivotal for the company’s growth. The decision reflects strategic shifts within Novo Nordisk as it navigates market demands and competition in diabetes treatment.
— new from Fortune
